High-tech drugs would get 12-yr market protection

Senators agreed Monday to give high-tech biologic drugs 12 years of market protection before generic versions can compete. (AP, 12:54 a.m.)

Oscient seeks bankruptcy protection

WALTHAM - Oscient Pharmaceuticals Corp. said yesterday it has filed for Chapter 11 bankruptcy protection, and sold its chronic bronchitis drug Factive. (Boston Globe, 7/13/09)

FDA questions J&J cancer drug data

WASHINGTON - Food and Drug Administration scientists are questioning whether study results are reliable enough to warrant approval for a new cancer drug from Johnson & Johnson . (Boston Globe, 7/13/09)

High-tech drugs would get 12-year monopoly

Senators agreed Monday to give high-tech biologic drugs a 12-year market monopoly before generic versions can compete. (AP, 7/13/09)

Amgen appoints Harvard business professor to board

Biotechnology company Amgen Inc. said Friday that Rebecca Henderson has been appointed to the board of directors. (AP, 7/10/09)